Mizuho says the market doesn’t understand Wave Life Sciences’ (WVE) share raise yesterday. “There are a couple of new details out this morning that strongly suggest this downward move can reverse this morning and continue over the course of today,” the analyst tells investors in a research note. The firm points out the SEC filing today said there was broad participation from existing investors, including GSK (GSK), and new investors in the financing. The Wave, GSK collaboration was formed in December 2022, well before Wave even announced that it had an INHBE program, Mizuho notes. This implies that if GSK wants the potential upside from Wave’s INHBE program, the only way to participate now is to buy the equity, says the firm. It keeps a Buy rating on Wave Life Sciences with a $10 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WVE:
- Wave Life Sciences 20M share Spot Secondary priced at $5.00
- Wave Life Sciences initiates dosing in the RestorAATion clinical trial program
- Wave Life Sciences $100M Spot Secondary; price range $5.00-$5.25
- Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
- Wave Life Sciences announces $100M ordinary shares offering